ResMed Inc. (NYSE: RMD, ASX: RMD) announced that Chief Financial Officer Brett Sandercock will retire effective May 4, 2026, after 27 years with the company, including 20 years as CFO. Aaron Bloomer has been appointed as his successor.

Bloomer joins ResMed from Exact Sciences, a cancer diagnostics company recently acquired by Abbott, where he served as Chief Financial Officer. He brings more than 17 years of global finance and operating leadership experience across healthcare and technology companies.

At Exact Sciences, Bloomer helped execute a strategic plan that delivered revenue growth, margin expansion and increased free cash flow. He also supported strategic mergers and acquisitions and new product launches to expand the company's portfolio.

Previously, Bloomer held senior finance leadership roles at Baxter International and 3M. During his tenure at 3M, he served in various positions including Senior Vice President of Financial Planning and Analysis, regional CFO based in China and global divisional CFO based in Japan.

"Aaron is a proven financial leader with deep experience driving operational discipline, strategic growth and global financial performance," said Mick Farrell, Chairman and CEO of ResMed.

Sandercock will serve as an advisor to the CEO through the end of calendar year 2027.

ResMed also reiterated its fiscal year 2026 outlook, including gross margin in the range of 62-63%, SG&A expenses in the range of 19-20%, R&D expenses in the range of 6-7% and effective tax rate in the range of 21-23%.

The San Diego-based company develops health technology focused on sleep, breathing and home-delivered care.